ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Prescription trends for combined oral contraceptives and thromboembolism incidence in Japan before and after public awareness events in 2013-2015.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveCombined oral contraceptives (COCs) for dysmenorrhea management have been covered by the Japanese universal health insurance system since 2008. Several public awareness events regarding COC prescriptions for dysmenorrhea were implemented between 2013 and 2015, including media reports on COC-related fatalities in 2013, drug safety alerts in 2014, and new clinical guidelines in 2015. This study aimed to examine the trends in patient characteristics, coagulation testing, and thromboembolism incidence before and after these events.
methodsWe used the JMDC claims database to identify patients with dysmenorrhea prescribed COCs between 2009 and 2021. We evaluated the annual trends in guideline-listed thromboembolism risk factors (age ≥ 40 years, obesity, and smoking), frequency of patients undergoing coagulation testing among patients prescribed COCs, and thromboembolism incidence.
resultsOf 860 840 patients with dysmenorrhea, 173 502 received COCs. The proportion of patients prescribed COCs decreased temporarily from 12.2% to 11.2% in 2014. The proportion of new COC prescriptions increased for women aged <40 years and decreased for those aged ≥40 years. The proportions of patients with obesity and smokers remained stable from 2016. The frequency of coagulation testing increased annually, rising sharply from 15% to 22% in 2014. The incidence of thromboembolism with treatment decreased from 11.8 to 9.9 per 10 000 person-years from 2016 to 2021.
conclusionAlthough no direct causal relationship is clear, public health awareness events might have influenced clinical practices, including the preferential selection of lower-risk patients and promotion of coagulation screening, possibly resulting in a decline in the incidence of thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.